Primary male hypogonadism presenting alongside erectile dysfunction and low serum testosterone defines a specific clinical scenario that calls for a dedicated, sequenced treatment strategy.
This protocol applies to men with primary hypogonadism in whom low serum testosterone co-occurs with erectile dysfunction. The presence of erectile dysfunction as a comorbidity directly influences which intervention is prioritised at the outset of management.
In this setting, initial management is anchored by a specific pharmacological class targeting erectile function: a phosphodiesterase type 5 inhibitor (PDE5I) as the first-line intervention.
The complete sequential algorithm — including subsequent steps and decision points — is available via the full protocol below.In hypogonadal men with erectile dysfunction start with a phosphodiesterase type 5 inhibitor (PDE5I) as first line treatment and add testosterone in case of a poor response to PDE5I treatment.
View source ↗